BCL2A1 and prostate carcinoma: examined the stereochemistry of Bl97C1, demonstrating that the (R,‐,R) enantiomer (displayed) inhibits the binding of BH3 peptides to Bcl‐xL, Bcl‐2, Mcl‐1, and Bfl‐1 with IC50 values of 0.31, 0.32, 0.20, and 0.62 μm (FITC‐Bak‐BH3‐only peptide).61 Additionally, inhibition of the cell growth of human prostate cancer, lung cancer, and BP3 B‐cell lymphoma cell lines with EC50 values of 0.13, 0.56, and 0.049 μm, respectively was demonstrated.